Skip to main content

Forbion Capital Partners — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

124
Companies
$12.0B
Total invested
$96.6M
Avg. check
17
Industries
Biotechnology 22Health Care 13Therapeutics 10Medical 9Life Science 5Biopharma 3+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 49–72 of 124
Mariana Oncology
September 2023

Mariana Oncology is a biotechnology research industry.

Bioinformatics · Watertown$175.0M Series B
Dualyx
May 2023

Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.

Biotechnology · Ghent$43.5M Series A
Complement Therapeutics
April 2023

Complement Therapeutics operates as a preclinical stage company.

Biotechnology · London$78.7M Series A
Amphista Therapeutics
December 2022

Amphista Therapeutics operates as a biopharmaceutical company.

Biopharma · CambridgeSeries B
Inversago Pharma
October 2022

Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists

Biopharma · Montréal$69.3M Series C
VectivBio
October 2022

VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.

Biotechnology · Basel$125.0M Post-IPO Equity
Achilles Therapeutics
July 2022

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

Biotechnology · London$4.1M Grant
Precirix
March 2022

Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.

Biotechnology · Brussels$88.2M Series B
NorthSea Therapeutics
December 2021

NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.

Biotechnology · Naarden$80.0M Series C
Anaveon
December 2021

Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.

Therapeutics · Bottmingen$119.7M Series B
Gyroscope Therapeutics
November 2021

Gyroscope Therapeutics is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.

Biotechnology · Stevenage$60.0M Corporate Round
Rectify Pharmaceuticals
October 2021

Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.

Biotechnology · Cambridge$100.0M Series A
NeRRe Therapeutics
July 2021

NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.

Biotechnology · Stevenage$27.6M Series B
Mestag Therapeutics
March 2026

Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology.

Biotechnology · Cambridge$40.0M Series Unknown
Tropic Biosciences
March 2026

Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.

Agriculture · London$105.0M Series C
Slate Medicines
February 2026

Slate Medicines develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention.

Biotechnology · Raleigh$130.0M Series A
Altesa
February 2026

Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments

Biotechnology · College Park$75.0M Series B
Beacon Therapeutics
January 2026

Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.

Biotechnology · Alachua$75.0M Series C
Corsera Health
January 2026

Corsera Health develops preventive RNA interference medicines that reduces cardiovascular disease risk before long-term damage occurs.

Biotechnology · Boston$80.0M Series A
Sidera Bio
December 2025

Sidera Bio harness human genetics, that helps in transformative medicines for patients.

Genetics · Copenhagen$109.0M Series A
Dyne Therapeutics
December 2025

Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.

Biotechnology · Cambridge$402.5M Post Ipo Equity
Crescent Biopharma
December 2025

Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.

Biotechnology · Rockville$185.0M Post Ipo Equity
Gate Bioscience
November 2025

Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.

Biotechnology · Brisbane$65.0M Series B
Braveheart Bio
November 2025

Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.

Biotechnology · San Francisco$185.0M Series A

Where Forbion Capital Partners invests

Biotechnology22
Health Care13
Therapeutics10
Medical9
Life Science5
Biopharma3

About Forbion Capital Partners's portfolio

How many companies has Forbion Capital Partners invested in?▸

Forbion Capital Partners has invested in 124 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Forbion Capital Partners invest in?▸

Forbion Capital Partners's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 17 different industry categories.

What is Forbion Capital Partners's largest investment?▸

Among tracked funding rounds, Dyne Therapeutics received $402.5M in a Post Ipo Equity round. Forbion Capital Partners's total known invested capital is $12.0B.

What is the average investment size for Forbion Capital Partners?▸

Forbion Capital Partners's average investment size is $96.6M across its portfolio of 124 companies.

What are Forbion Capital Partners's most recent investments?▸

Recent Forbion Capital Partners portfolio additions include Mariana Oncology, Dualyx, Complement Therapeutics, Amphista Therapeutics, Inversago Pharma. These companies were founded in 2020 or later.

Reach the founders behind these 124 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →